Electrotherapy Systems Market Size, Share, & Trends by 2030

[Research Report] The electrotherapy systems market size was valued at US$ 4.21 billion in 2022 and is expected to reach US$ 8.57 billion by 2030. The market is estimated to register a CAGR of 9.3% from 2022 to 2030.

Market Insights and Analyst View:

The report includes growth prospects owing to the current electrotherapy systems market trends and their foreseeable impact during the forecast period.

An electrotherapy system is a medical device used to stimulate a patient's muscle function by passing electric currents through their tissues. Electrotherapy is useful in treating acute post-traumatic and post-surgical pain, facilitating wound healing and muscle spasm relaxation, preventing and mitigating disuse atrophy, aiding muscle rehabilitation, maintaining and increasing range of motion, and relieving acute post-traumatic and post-surgical pain. Electrotherapy units typically consist of a battery-operated device wired to adhesive electrode pads that make contact with the skin. Factors such as the increasing prevalence of sports injuries and strategic initiatives by manufacturers propel the electrotherapy systems market.

Market Drivers:

The increasing incidences of chronic diseases such as cancer, cardiovascular diseases, neurovascular diseases, and musculoskeletal diseases are likely to drive the growth of the pain management devices market. These diseases critically affect a person's health by lowering immunity and resulting in chronic pain. The incidences of chronic diseases are most commonly seen in adults and the geriatric population. For instance, according to the Centers for Disease Control and Prevention data between 2019 and 2021, the prevalence of chronic pain among US adults ranged from 20.5% to 21.8%, and high-impact chronic pain ranged from 6.9% to 7.8%. During 2021, an estimated 51.6 million US adults experienced chronic pain, and 17.1 million experienced high-impact chronic pain.

Furthermore, the incidences of chronic pain are commonly seen among athletes, sportspersons, and people living with past injuries. Chronic pain incidences increase the dependency of a person on others for various daily tasks. Therefore, pain management is essential to carry out normal daily routine. The electrotherapy systems provide relief for longer durations and also improve their health. Therefore, the increasing incidences of chronic diseases propels the electrotherapy systems market growth.

According to the report titled "Spinal Cord Injury Facts and Stats" published in July 2022, ∼17,700 Americans suffer from a spinal cord injury yearly, of which ∼78% are men with an average age of 43. As per estimates by the National Safety Council of the United States, nearly 3.2 million people in the US received treatments in emergency departments for injuries involving sports and recreational equipment in 2021. Therefore, the high incidence of spinal cord injuries propels the electrotherapy systems market growth.

The Federal Food, Drug, and Cosmetic Act includes electrical muscle stimulators (EMS) in the category of devices. The FDA is responsible for regulating the sale of all electrical muscle stimulators in the US per the legislation and the agency's rules. Thus, companies cannot lawfully sell their stimulators unless they have complied with all applicable FDA premarket regulatory procedures. The majority of electrical muscle stimulators that the FDA has evaluated are meant to be used in physical therapy and rehabilitation under a physician's supervision. Companies must demonstrate to the FDA that their EMS devices can be used in that environment both safely and effectively if they want to sell them to consumers directly. Before they can lawfully sell their products, companies that market EMS devices must adhere to the relevant FDA premarket regulatory criteria. Thus, stringent regulatory specifications for electrotherapy products limit the electrotherapy systems market growth.

Customize Research To Suit Your Requirement

We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.

Get 10% FREE CUSTOMIZATION

Electrotherapy Systems Market: Strategic Insights

Electrotherapy Systems Market

• 
  CAGR (2022 - 2030)

  9.3%
• Market Size 2022
  US$ 4.21 Billion
• Market Size 2030
  US$ 8.57 Billion

Market Dynamics

GROWTH DRIVERS

• Rising prevalence of chronic pain
• Demand for non-invasive treatments

FUTURE TRENDS

• Portable and home-based devices
• Integration with IoT for monitoring

OPPORTUNITIES

• Increasing awareness of electrotherapy
• Partnerships with healthcare providers

Key Players

• BTL
• DJO LLC
• Omron Healthcare Inc
• Abbott
• Boston Scientific Corporation
• Medtronic
• Nevro Corp
• Phoenix Healthcare
• Eme srl

Regional Overview

• North America
• Europe
• Asia-Pacific
• South and Central America
• Middle East and Africa

Market Segmentation

Product

• Percutaneous Electrical Nerve Stimulation
• Spinal Cord Stimulation
• Transcutaneous Electrical Nerve Stimulation
• Micro-Current Therapy
• Interferential Current Therapy
• Electro-Acupuncture
• Pulsed Short Wave Diathermy
• Transcutaneous Spinal Electroanalgesia

Application

• Neuromuscular Dysfunction
• Pain Management
• Acute & Chronic Edema
• Sports Injury Treatment
• Iontophoresis
• Urine & Fecal Incontinence

End User

• Hospitals
• Clinics
• Long Term Care Centers
• Rehabilitation Centers

Download Free Sample

   Buy Now   

• Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.

Report Segmentation and Scope:

The electrotherapy systems market analysis has been carried out by considering the following segments: product, application, and end user.

 

Segmental Analysis:

The electrotherapy systems market, by product, is segmented into percutaneous electrical nerve stimulation (PENS), transcutaneous electrical nerve stimulation (TENS), spinal cord stimulation (SCS), micro-current therapy, interferential current therapy (IC), electro-acupuncture (EA), pulsed short wave diathermy (PSWD), transcutaneous spinal electroanalgesia (TSE), and others. The spinal cord stimulation segment held the largest share of the market in 2022. It is likely to register the highest CAGR during 2022–2030. Spinal cord stimulation has been in use in medical facilities for years. Cervical and lumbar radiculitis, failed back surgery syndrome, complex regional pain syndrome, and neuropathy are a few of the conditions that can be assisted by the therapy. Spinal cord stimulation is an efficacious, safe, and cost-effective method of chronic pain management. Newer spinal cord stimulation technologies are being introduced to treat an extended range of clinical indications, including visceral and ischemic pain, with the potential for further improved efficacy.

By application, the market is segmented into neuromuscular dysfunction, pain management, acute and chronic edema, sports injury treatment, iontophoresis, urine and fecal incontinence, and others. The pain management segment held the largest share of the electrotherapy systems market share in 2022. It is likely to register the highest CAGR during 2022–2030. The market growth of this segment is attributed to the burgeoning prevalence of trauma and sports injuries. According to data released by the World Health Organization in March 2022, nearly 30 million children and teenagers participate in organized sports and more than 3.5 million injuries are reported every year. Furthermore, it was also estimated that 570,000 people faced traumatic pain in the US in 2021. An upsurge in the occurrence of back pain and neck pain also results in a heightened demand for electrotherapy to treat chronic pain.

By end user, the electrotherapy systems market is segmented into hospitals, clinics, long-term care centers, rehabilitation centers, and others. In 2022, the hospitals segment accounted for the largest electrotherapy systems market share.

Regional Analysis:

The scope of the electrotherapy systems market report includes North America (US, Canada, and Mexico), Europe (Spain, UK, Germany, France, Italy, and Rest of Europe), Asia Pacific (South Korea, China, India, Japan, Australia, and Rest of Asia Pacific), Middle East & Africa (South Africa, Saudi Arabia, UAE, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America). In terms of revenue, North America dominated the electrotherapy systems market in 2022. Population aging is a major factor that can be associated with the elevated demand for electrotherapy in the region. According to WHO data released in December 2022, 73 million individuals in North America are estimated to be of age 65 or above by 2053. The same source states that 17% of the US population above 65 years of age are experiencing back discomfort and spinal injuries.

Electrotherapy Systems Market Report Scope

Download Free Sample

   Buy Now   

• Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.

Competitive Landscape and Key Companies:

The electrotherapy systems market report is focused on prominent players in the market. These include BTL, DJO LLC, Omron Healthcare Inc, Abbott, Boston Scientific Corporation, Medtronic, Nevro Corp, Phoenix Healthcare, Eme srl, and Pure Care. These companies focus on new technologies, upgrading existing products, and market expansions to meet the growing consumer demand worldwide. The electrotherapy systems market forecast can help stakeholders plan their growth strategies.

• In January 2022, Medtronic plc, a global leader in healthcare technology, received approval from the US Food and Drug Administration (FDA) for its Intellis (rechargeable) and Vanta (recharge-free) neurostimulators for the treatment of chronic pain associated with diabetic peripheral neuropathy (DPN). This new indication offers DPN patients access to Medtronic's industry-leading SCS portfolio of rechargeable and recharge-free solutions, including multiple programming options to personalize patient therapy, unrestricted MRI access, and unrivaled battery chemistry and performance, along with the Medtronic TYRX Neuro Absorbable Antibacterial Envelope.
• In March 2021, the FDA approved an application by Medtronic plc for the revised commercial labeling for its Intellis platform with Differential Target Multiplexed (DTM) programming. The new labeling was meant to include study outcomes from a multicenter randomized control trial, mentioning superior back pain relief conferred by DTM SCS compared to conventional SCS.
• In September 2020, Boston Scientific launched the WaveWriter Alpha portfolio of SCS systems in Europe. The four MRI conditional, Bluetooth-enabled implantable pulse generators (IPGs) launched in this portfolio offer greater personalization based on patient needs. The products also include rechargeable and non-rechargeable options, and access to waveforms covering multiple areas of pain.